|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM60 |
Gene summary for TMEM60 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM60 | Gene ID | 85025 |
| Gene name | transmembrane protein 60 | |
| Gene Alias | C7orf35 | |
| Cytomap | 7q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H2L4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85025 | TMEM60 | LZE4T | Human | Esophagus | ESCC | 3.93e-09 | 3.03e-01 | 0.0811 |
| 85025 | TMEM60 | LZE8T | Human | Esophagus | ESCC | 9.72e-03 | 1.13e-01 | 0.067 |
| 85025 | TMEM60 | LZE20T | Human | Esophagus | ESCC | 8.20e-13 | 2.94e-01 | 0.0662 |
| 85025 | TMEM60 | LZE22T | Human | Esophagus | ESCC | 3.67e-11 | 4.62e-01 | 0.068 |
| 85025 | TMEM60 | LZE24T | Human | Esophagus | ESCC | 3.84e-23 | 6.02e-01 | 0.0596 |
| 85025 | TMEM60 | LZE21T | Human | Esophagus | ESCC | 1.26e-02 | 2.23e-01 | 0.0655 |
| 85025 | TMEM60 | LZE6T | Human | Esophagus | ESCC | 6.75e-03 | 2.19e-01 | 0.0845 |
| 85025 | TMEM60 | P1T-E | Human | Esophagus | ESCC | 1.46e-07 | 4.33e-01 | 0.0875 |
| 85025 | TMEM60 | P2T-E | Human | Esophagus | ESCC | 1.78e-21 | 3.38e-01 | 0.1177 |
| 85025 | TMEM60 | P4T-E | Human | Esophagus | ESCC | 7.91e-24 | 5.91e-01 | 0.1323 |
| 85025 | TMEM60 | P5T-E | Human | Esophagus | ESCC | 9.87e-16 | 2.40e-01 | 0.1327 |
| 85025 | TMEM60 | P8T-E | Human | Esophagus | ESCC | 8.47e-25 | 3.44e-01 | 0.0889 |
| 85025 | TMEM60 | P9T-E | Human | Esophagus | ESCC | 2.80e-22 | 6.12e-01 | 0.1131 |
| 85025 | TMEM60 | P10T-E | Human | Esophagus | ESCC | 4.33e-20 | 3.55e-01 | 0.116 |
| 85025 | TMEM60 | P11T-E | Human | Esophagus | ESCC | 7.63e-15 | 3.89e-01 | 0.1426 |
| 85025 | TMEM60 | P12T-E | Human | Esophagus | ESCC | 2.79e-31 | 5.08e-01 | 0.1122 |
| 85025 | TMEM60 | P15T-E | Human | Esophagus | ESCC | 1.26e-21 | 5.02e-01 | 0.1149 |
| 85025 | TMEM60 | P16T-E | Human | Esophagus | ESCC | 1.41e-43 | 7.93e-01 | 0.1153 |
| 85025 | TMEM60 | P17T-E | Human | Esophagus | ESCC | 1.59e-10 | 2.96e-01 | 0.1278 |
| 85025 | TMEM60 | P19T-E | Human | Esophagus | ESCC | 8.99e-06 | 4.14e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM60 | SNV | Missense_Mutation | novel | c.74T>G | p.Leu25Trp | p.L25W | Q9H2L4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| TMEM60 | insertion | Nonsense_Mutation | novel | c.42_43insGGACATGAAATTTAAATTTCAAATGA | p.Phe15GlyfsTer5 | p.F15Gfs*5 | Q9H2L4 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| TMEM60 | SNV | Missense_Mutation | c.21N>C | p.Gln7His | p.Q7H | Q9H2L4 | protein_coding | tolerated(1) | benign(0.182) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| TMEM60 | SNV | Missense_Mutation | novel | c.397N>C | p.Asp133His | p.D133H | Q9H2L4 | protein_coding | deleterious_low_confidence(0.03) | benign(0.39) | TCGA-C5-A1M7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM60 | SNV | Missense_Mutation | novel | c.334C>T | p.Pro112Ser | p.P112S | Q9H2L4 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM60 | insertion | Frame_Shift_Ins | rs749773249 | c.231dupA | p.Ala78SerfsTer10 | p.A78Sfs*10 | Q9H2L4 | protein_coding | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TMEM60 | deletion | Frame_Shift_Del | rs780465472 | c.231delN | p.Ala78ProfsTer11 | p.A78Pfs*11 | Q9H2L4 | protein_coding | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TMEM60 | deletion | Frame_Shift_Del | rs780465472 | c.231delA | p.Ala78ProfsTer11 | p.A78Pfs*11 | Q9H2L4 | protein_coding | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TMEM60 | deletion | Frame_Shift_Del | rs780465472 | c.231delA | p.Ala78ProfsTer11 | p.A78Pfs*11 | Q9H2L4 | protein_coding | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| TMEM60 | deletion | Frame_Shift_Del | rs780465472 | c.231delN | p.Ala78ProfsTer11 | p.A78Pfs*11 | Q9H2L4 | protein_coding | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |